Bulk Pharmaceutical API Sources for METYRAPONE

Bulk Pharmaceutical API Sources for METYRAPONE

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jhiQ@@INAdTTTbRarrk^BtEP@@@@@
Sigma-Aldrich		856525_ALDRICH
NovoSeek		4174
MolPort		MolPort-001-794-644
NIH Clinical Collection		SAM002297829
ABI Chem		AC1L1HKV
ABI Chem		AC1Q1LHX

Metyrapone Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis

Last updated: February 19, 2026

This report analyzes the global supply landscape for bulk active pharmaceutical ingredient (API) metyrapone, identifying key manufacturers, regulatory considerations, and market dynamics relevant to pharmaceutical companies and investors. The analysis focuses on identifying reliable, compliant, and cost-effective sourcing options.

What is the Regulatory Landscape for Metyrapone API Production?

The production of metyrapone API is subject to stringent regulatory oversight by global health authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must adhere to Current Good Manufacturing Practices (cGMP) to ensure the quality, safety, and efficacy of the API. This involves rigorous quality control processes, detailed batch documentation, and adherence to pharmacopoeial standards such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.).

Key regulatory requirements include:

• cGMP Compliance: Facilities must demonstrate and maintain compliance with cGMP guidelines. This encompasses facility design, equipment validation, personnel training, raw material control, process validation, and finished product testing. Regular inspections by regulatory bodies are standard.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the API manufacturing process, including facilities, equipment, quality control procedures, and stability data. Pharmaceutical companies can reference these DMFs in their drug product applications.
• Pharmacopoeial Standards: Metyrapone API must meet specifications outlined in relevant pharmacopoeias (e.g., USP, Ph. Eur.). These monographs define identity, purity, assay, and impurity limits.
• Impurity Profiling: Manufacturers are required to identify and quantify impurities present in the API. Limits for specific impurities are defined by regulatory guidelines and pharmacopoeias.
• Stability Testing: Comprehensive stability studies are necessary to establish the retest period or expiry date of the API under defined storage conditions.
• Country-Specific Registrations: Depending on the target market, API manufacturers may need to register their product and facility in specific countries, requiring additional documentation and potentially local inspections.

The ability to consistently meet these regulatory demands is a primary differentiator for API suppliers and directly impacts the ease with which pharmaceutical companies can secure regulatory approval for their finished drug products.

Who are the Primary Global Manufacturers of Metyrapone API?

The global supply of metyrapone API is concentrated among a limited number of manufacturers, primarily located in Asia and, to a lesser extent, Europe and North America. These manufacturers vary in scale, regulatory compliance history, and production capacity.

Key manufacturers and their general geographic locations include:

• Asia:
  • India: Several Indian API manufacturers are significant suppliers. Companies often leverage cost-effective production capabilities and a well-established pharmaceutical infrastructure. Regulatory compliance, particularly cGMP adherence and DMF filings, is a critical factor for these suppliers.
  • China: Chinese manufacturers also play a role in the global supply chain. Similar to India, cost competitiveness is a driver, with an increasing focus on improving cGMP standards and regulatory documentation.
• Europe:
  • Germany: Historically, European manufacturers have been involved in metyrapone production, often emphasizing high-quality standards and established regulatory track records.
• North America:
  • While some North American companies may be involved in pharmaceutical formulations using metyrapone, large-scale bulk API manufacturing within the region is less common compared to Asian suppliers.

Specific company names and their production volumes are often proprietary and subject to change based on market demand and strategic decisions. However, the general trend indicates a strong presence of Indian and Chinese manufacturers due to competitive pricing and expanding manufacturing capacities. Pharmaceutical companies typically engage in thorough due diligence to vet potential suppliers, including site audits, quality agreement negotiations, and review of regulatory documentation.

What are the Key Quality and Purity Specifications for Metyrapone API?

Metyrapone API must meet stringent quality and purity specifications to be suitable for pharmaceutical use. These specifications are defined by pharmacopoeias and internal company standards. The primary quality attributes include:

• Assay: The content of metyrapone in the API. Typically, the assay should be within a narrow range, for example, 98.0% to 102.0% on an anhydrous basis.
• Identification: Tests to confirm that the substance is indeed metyrapone, often using techniques like infrared (IR) spectroscopy or high-performance liquid chromatography (HPLC).
• Purity: This encompasses several parameters:
  • Related Substances/Impurities: Limits are set for known and unknown impurities. These can arise from synthesis byproducts, degradation products, or residual solvents. Specific impurity limits are critical and are often detailed in pharmacopoeial monographs or DMFs. For instance, limits for specific known impurities might be set at not more than 0.10% or 0.15%.
  • Residual Solvents: Limits are defined for solvents used during the manufacturing process, according to guidelines like ICH Q3C. Common solvents and their maximum allowable limits (e.g., ppm) must be controlled.
  • Heavy Metals: Limits for heavy metal contamination are essential for patient safety.
  • Water Content: Determined by Karl Fischer titration, the water content must be within specified limits (e.g., not more than 0.5%).
  • Sulphated Ash/Residue on Ignition: A measure of inorganic impurities, typically limited to a low percentage (e.g., not more than 0.1%).
• Physical Characteristics: Appearance (e.g., white to off-white crystalline powder), particle size distribution (which can impact formulation and dissolution), and solubility are also important.
• Microbial Limits: The API must meet specified limits for microbial contamination, especially if it is intended for sterile drug products.

Manufacturers provide a Certificate of Analysis (CoA) with each batch, detailing the results of testing against these specifications. Pharmaceutical companies conduct their own incoming quality control testing to verify these results.

What are the Market Dynamics and Pricing Considerations for Metyrapone API?

The market dynamics for metyrapone API are influenced by several factors, including global demand for its therapeutic applications, the competitive landscape of API manufacturers, and regulatory compliance costs.

• Demand Drivers: Metyrapone is primarily used in the diagnosis and treatment of Cushing's syndrome, a condition characterized by excess cortisol production. It also has research applications in endocrinology. Demand is thus linked to the prevalence of these conditions and the availability of diagnostic and therapeutic regimens.
• Supply Chain Concentration: As noted, the number of primary manufacturers is relatively small, which can influence supply stability and pricing power. Dependence on a few key suppliers can create risks during periods of disruption.
• Pricing: Pricing for metyrapone API is subject to variations based on:
  • Volume: Larger order volumes generally command lower per-unit prices.
  • Quality and Regulatory Status: APIs from manufacturers with well-established cGMP compliance, robust regulatory documentation (e.g., approved DMFs), and a history of successful regulatory inspections typically command premium pricing.
  • Geographic Origin: Manufacturing costs vary significantly by region, with Asian manufacturers generally offering lower prices compared to European or North American counterparts due to labor and operational expenses.
  • Contractual Agreements: Long-term supply agreements can provide price stability and volume commitments.
  • Market Competition: While the number of manufacturers is limited, competition still exists, influencing price negotiations.
• Cost of Compliance: The significant investment required for maintaining cGMP standards, conducting extensive testing, and preparing regulatory filings adds to the overall cost of API production. These costs are factored into the final API price.
• Intellectual Property: While the primary patents for metyrapone have long expired, process patents for improved synthesis routes or polymorphic forms could theoretically influence the supply chain, though this is less common for older, established APIs.

Pharmaceutical companies must balance cost-effectiveness with supply chain reliability and regulatory compliance when sourcing metyrapone API.

What are the Challenges and Opportunities in Sourcing Metyrapone API?

Sourcing metyrapone API presents a combination of challenges and opportunities for pharmaceutical developers and manufacturers.

Challenges:

• Limited Supplier Base: The relatively concentrated number of manufacturers can lead to potential supply chain vulnerabilities. Dependence on a few key suppliers increases the risk of shortages or disruptions due to geopolitical events, manufacturing issues, or regulatory actions.
• Regulatory Scrutiny: Ensuring that API suppliers consistently meet evolving global regulatory standards (cGMP, impurity controls) is an ongoing challenge. Non-compliance can lead to batch rejections, costly recalls, or delays in drug product approval.
• Quality Variability: While pharmacopoeial standards provide a baseline, there can be subtle differences in API quality and impurity profiles between manufacturers. Robust incoming quality control and supplier qualification are essential.
• Geopolitical and Supply Chain Risks: Reliance on APIs manufactured in specific regions can expose companies to risks associated with trade policies, tariffs, and logistical disruptions.
• Lead Times: The production and delivery of bulk API can involve significant lead times, requiring careful inventory management and forecasting.

Opportunities:

• Strategic Partnerships: Establishing strong, long-term relationships with reliable API manufacturers can lead to preferential pricing, guaranteed supply, and collaborative problem-solving.
• Diversification of Supply: Identifying and qualifying multiple suppliers across different geographic regions can mitigate supply chain risks and provide leverage in negotiations.
• Technological Advancements: Exploring suppliers who have invested in process improvements or advanced analytical techniques may offer higher purity APIs or more efficient production methods.
• Emerging Markets: While established manufacturers dominate, monitoring emerging suppliers with increasing regulatory capabilities in regions like Southeast Asia could present future sourcing options.
• Vertical Integration: For large pharmaceutical companies, considering backward integration into API manufacturing, or strategic investments in API facilities, could offer greater control over supply and quality, though this is a capital-intensive strategy.

Successfully navigating these challenges and capitalizing on opportunities requires a proactive and strategic approach to API sourcing and supplier management.

Key Takeaways

• The global supply of metyrapone API is primarily driven by manufacturers in India and China, with European suppliers also active.
• Strict adherence to cGMP and comprehensive regulatory documentation (e.g., DMFs) are critical for API manufacturers.
• Quality and purity specifications, including assay, related substances, residual solvents, and heavy metals, are defined by pharmacopoeial standards and ICH guidelines.
• Market pricing is influenced by volume, regulatory compliance, geographic origin, and contractual agreements.
• Challenges in sourcing include a limited supplier base and ongoing regulatory scrutiny, while opportunities lie in strategic partnerships and supply chain diversification.

FAQs

1. What is the typical lead time for ordering bulk metyrapone API? Lead times can vary significantly but commonly range from 8 to 16 weeks from order placement to delivery, depending on the supplier's production schedule, current inventory, and logistics.
2. Are there any patent restrictions on sourcing metyrapone API? The primary patents for metyrapone have expired. However, specific synthesis processes or polymorphic forms might be protected by current patents, which could influence sourcing options or require licensing.
3. What is the recommended approach for qualifying a new metyrapone API supplier? Qualification typically involves a comprehensive supplier audit (cGMP compliance, quality systems), review of regulatory documentation (DMF, site master file), sample testing of multiple batches, and establishment of a robust quality agreement.
4. How do impurities in metyrapone API affect drug product quality and regulatory approval? Impurities can impact the safety and efficacy of the finished drug product and are subject to strict limits set by regulatory agencies. Exceeding these limits can lead to batch rejection, delays in approval, or product recalls.
5. What is the role of the Drug Master File (DMF) in sourcing metyrapone API? A DMF provides confidential, detailed information about the manufacturing process, facilities, and controls of the API. Pharmaceutical companies reference the DMF in their drug product applications, allowing regulatory agencies to review the API's manufacturing information without disclosing proprietary data to the drug product applicant.

Citations

[1] United States Pharmacopeia. (Accessed [Date of Access]). Metyrapone Monograph. USP-NF. [2] European Directorate for the Quality of Medicines & HealthCare. (Accessed [Date of Access]). Metyrapone Monograph. Ph. Eur. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). Impurities: Guideline for Residual Solvents Q3C(R2). [4] U.S. Food and Drug Administration. (Accessed [Date of Access]). Guidance for Industry on cGMP for APIs.